We are 2-Butyl-5-nitrobenzofuran CAS:133238-87-6 manufacturer and supplier in China, Pls send inquiry of to email@example.com of visit www.nbinno.com our official website should you have any interests
Chemical Name: 2-Butyl-5-nitrobenzofuran
Physical and Chemical Properties:
Density: 1.2±0.1 g/cm3
Boiling point:329.7±22.0 °C at 760 mmHg
Melting point: /
Flash point:153.2±22.3 °C
Refractive index: 1.586
Appearance:Bright Yellow Low Melting Solid
25kg cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Dronedarone hydrochloride CAS:141625-93-6
Intermediates of Dronedarone CAS:141626-36-0
Related News: Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.2-Ethoxybenzoic acid CAS:134-11-2 As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters.2-CLORO-6-FLUOROPIRIDINA CAS:20885-12-5 Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.5-bromopyridine-3-carbonitrile CAS:35590-37-5 Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?